Evidence map›Paper›PMID 37390095›Full record

ArticlePloS one2023

A retrospective view of the relationship of soluble Fas with anemia and outcomes in chronic kidney disease.

Jessica Felício Andrade, Maria A Dalboni, Otavio Candido Clemente, Beatriz Moreira Silva, Barbara Formaggio Domingues, Adelson Marcal Rodrigues, Maria Eugenia Canziani, Abolfazl Zarjou, Miguel Cendoroglo, Miguel Angelo Goes

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Jessica Felício AndradeDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-7538-477X
Maria A DalboniDepartment of Research and Graduate, Universidade Nove de Julho/UNINOVE, São Paulo, Brazil.
Otavio Candido ClementeDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Beatriz Moreira SilvaDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Barbara Formaggio DominguesDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Adelson Marcal RodriguesDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Maria Eugenia CanzianiDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Abolfazl ZarjouDivision of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Miguel CendorogloDepartment of Superintendence and Board, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Miguel Angelo GoesDivision of Nephrology, Federal University of São Paulo, São Paulo, Brazil.
Universidade Federal de São Paulo · BRHospital Israelita Albert Einstein · BRUniversidade Nove de Julho · BRUniversity of Alabama at Birmingham · US

Funding

Regulation of Macrophage Phenotype by Ferritin Heavy Chain in CKDR01DK134402 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Abolfazl Zarjou · 2023 to 2026
$1.6M
NIDDK NIH HHS R01 DK134402
6 · The paper itself

Abstract

backgroundAnemia is common in chronic kidney disease (CKD) and is associated with outcomes. In addition, serum soluble Fas (sFas) levels are related to anemia and erythropoietin (EPO) resistance.

objectivesFirstly, to compare clinical data and serum levels of sFas, EPO, and pro-inflammatory markers between patients with non-dialytic CKD (NDD-CKD) and healthy subjects. Subsequently, to compare and evaluate the relationship of serum EPO, sFas levels with anemia, and outcomes in patients with NDD-CKD over a long follow-up period.

methodsWe performed a retrospective study in 58 NDD-CKD patients compared with 20 healthy subjects on complete blood count, kidney function, serum EPO, sFas, and inflammatory markers (CRP, IL- 6, and IFN-γ) at baseline. We then compared the same baseline data between patients with NDD-CKD who evolved to anemia and those who did not have anemia over the follow-up. We also evaluated the frequency of outcomes in patients with CKD with higher sFas levels. Finally, we performed a multivariate analysis of factors associated with CKD anemia.

resultsThere were lower eGFR and Hb but higher serum inflammatory markers, sFas levels, sFas/eGFR, and EPO/Hb ratios in patients with NDD-CKD. Comparatively, on the other hand, NDD-CKD patients with anemia had lower eGFR but were older, had more diabetes, and had higher sFas/ eGFR, EPO/Hb ratios, and serum levels of IL-6 and sFas than NDD-CKD without anemia for an extended period. In addition, there was an association in a multivariate analysis of diabetes, age, and sFas levels with kidney anemia. Furthermore, there were higher frequencies of outcomes in increased serum sFas levels.

conclusionAs an elective risk factor, serum sFas levels, in addition to age and diabetes, were independently associated with kidney anemia for an extended period. Thus, more studies are necessary to analyze the proper relationship of sFas with kidney anemia and its outcomes and therapy in CKD.

Indexed as

AnemiaRenal Insufficiency, ChronicHealthy VolunteersHumansMultivariate AnalysisRetrospective Studies

Identifiers

PMID37390095
PMCPMC10313056
OpenAlexW4382751461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.